Stock Market Reviews

ECOR (electroCore, Inc.) News

Get the latest news, insights, and market updates on ECOR (electroCore, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Analysts Expect Breakeven For electroCore, Inc. (NASDAQ:ECOR) Before Long
  We feel now is a pretty good time to analyse electroCore, Inc.'s ( NASDAQ:ECOR ) business as it appears the company may...
  Dec 24, 2025 - $ECOR
• TAC-STIM Demonstrates Significant Performance Improvements in Active-Duty United States Air Force Airmen
  ROCKAWAY, N.J., Dec. 02, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today announced the publication of a peer reviewed paper titled “Non-Invasive Transcutaneous Vagal Nerve Stimulation Enhances Mood, Task Performance, and Learning in a High-Stress Military Training Environment” which will be presented at the Applied Human Factors and Ergonomics (AHFE2025) Conference on December 8, 2025. The paper presents result
  Dec 2, 2025 - $ECOR
• Investors in electroCore (NASDAQ:ECOR) from five years ago are still down 74%, even after 28% gain this past week
  electroCore, Inc. ( NASDAQ:ECOR ) shareholders should be happy to see the share price up 28% in the last week. But will...
  Nov 13, 2025 - $ECOR
• electroCore to Participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
  ROCKAWAY, N.J., Nov. 10, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that management will participate at the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum. The conference will take place in New York on Thursday, November 20, 2025 at The Westin NY Grand Central Hotel. Management will host one-on-one meetings throughout the day. Investors who wish to request a meeting should
  Nov 10, 2025 - $ECOR
• electroCore, Inc. (ECOR) Reports Q3 Loss, Beats Revenue Estimates
  electroCore (ECOR) delivered earnings and revenue surprises of -11.11% and +10.69%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?
  Nov 5, 2025 - $ECOR
• electroCore Announces Third Quarter 2025 Financial Results
  Net sales of $8.7 million increased 33% vs. Q3 2024; YTD net sales of $22.8 million increased 26% vs. first nine months of 2024 Cash, cash equivalents, restricted cash, and marketable securities (“Total Cash”) of $13.2 million as of September 30, 2025 Company to host a conference call and webcast today, November 5, 2025, at 4:30 p.m. EDT ROCKAWAY, N.J., Nov. 05, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR) (“electroCore” or the “Company”), a bioelectronic technology company, today a
  Nov 5, 2025 - $ECOR
• Analysts Estimate electroCore, Inc. (ECOR) to Report a Decline in Earnings: What to Look Out for
  electroCore (ECOR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
  Oct 29, 2025 - $ECOR
• electroCore to Announce Third Quarter September 30, 2025 Financial Results on Wednesday, November 5, 2025
  ROCKAWAY, N.J., Oct. 23, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that it will report financial results for the third quarter ended September 30, 2025, after the close of the market on Wednesday, November 5, 2025. Management will host a webinar at 4:30 PM EST to review the financial results and answer questions. Investors can access the webinar using the details below: Wednesday, November 5, 4:30 PM
  Oct 23, 2025 - $ECOR
• electroCore Announces Inducement Grant under NASDAQ Listing Rule 5635(c)(4)
  ROCKAWAY, N.J., Oct. 03, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (the “Company”), (NASDAQ: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced that Jennifer Hayes will be joining electroCore, effective October 6, 2025, as the Company’s Vice President, Human Resources and Employee Success. The Compensation Committee of electroCore’s Board of Directors granted 10,000 restricted stock units (“RSUs”) to Ms. Hayes in connection with the commencement of her employ
  Oct 3, 2025 - $ECOR
• gammaCore® Non-Invasive Vagus Nerve Stimulation (nVNS) as an Adjunctive Treatment Associated with Improvements in Persistent Post-Concussion Symptoms
  ROCKAWAY, N.J., Sept. 30, 2025 (GLOBE NEWSWIRE) -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, today announced the publication of a peer-reviewed study in Frontiers in Neurology demonstrating the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in reducing persistent symptoms associated with mild traumatic brain injury (mTBI). “The CDC reports approximately 2.5 million emergency department visits each year in the United
  Sep 30, 2025 - $ECOR